mesothelioma
News/ News/ News/ Oncology/ R&D
BMS’ Opdivo aces trial in asbestos-linked lung cancer
Phil Taylor
Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, mesothelioma, Oncology, Opdivo, Yervoy
0 Comment
X
BMS’ Opdivo aces trial in asbestos-linked lung cancer
https://pharmaphorum.com/news/bms-opdivo-aces-trial-in-asbestos-linked-lung-cancer/
Digital/ News/ News/ News/ Oncology/ Top stories
Owkin’s machine learning tech to inform mesothelioma trials
X
Owkin’s machine learning tech to inform mesothelioma trials
https://pharmaphorum.com/news/owkins-machine-learning-tech-gives-mesothelioma-prognosis-and-survival-insights/
Cancer/ News/ News/ News/ Oncology/ Pharma Market Access/ R&D/ UK & Europe
BI drug named Promising Innovative Medicine in mesothelioma
Andrew McConaghie
Boehringer Ingelheim, Early Access to Medicines Scheme, mesothelioma, MHRA, Promising Innovative Medicine, UK market access, Vargatef
0 Comment
X
BI drug named Promising Innovative Medicine in mesothelioma
https://pharmaphorum.com/news/bi-drug-named-promising-innovative-medicine-mesothelioma/